Stuttgart
15.05.26 | 21:33
4,580 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | INVENTIVA: Inventiva to Present Abstracts at the EASL Congress 2026 | 289 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), May 13, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 01.05. | Inventiva appoints Axel-Sven Malkomes as Chief Financial Officer | 9 | PMLiVE | ||
| 22.04. | Inventiva announces CFO appointment | 2 | Seeking Alpha | ||
| INVENTIVA SA ADR Aktie jetzt für 0€ handeln | |||||
| 22.04. | Inventiva stärkt Führungsteam vor entscheidenden Studienergebnissen | 11 | Investing.com Deutsch | ||
| 22.04. | INVENTIVA: Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor | 538 | GlobeNewswire (Europe) | Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inventiva's organizational build-out as it advances toward potential commercialization.Axel-Sven Malkomes... ► Artikel lesen | |
| 22.04. | Inventiva S.A. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 08.04. | INVENTIVA: Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F | 599 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), April 8, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 08.04. | Inventiva S.A. - 20-F, Annual and transition report of foreign private issuers | 4 | SEC Filings | ||
| 07.04. | Piper Sandler reiterates Inventiva stock rating ahead of trial | 11 | Investing.com | ||
| 31.03. | MASH-Studie: Leerink bekräftigt positive Einschätzung für Inventiva | 11 | Investing.com Deutsch | ||
| 31.03. | Leerink reiterates Inventiva stock rating on MASH trial progress | 2 | Investing.com | ||
| 31.03. | Stifel cuts Inventiva stock price target on dilution concerns | 3 | Investing.com | ||
| 30.03. | INVENTIVA: Inventiva reports 2025 full year results and provides a business update | 1.374 | GlobeNewswire (Europe) | Revenues of €4.5 million for the full year of 2025Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits1 as at December 31, 2025Completed a U.S. registered public offering... ► Artikel lesen | |
| 23.03. | INVENTIVA: Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results | 598 | GlobeNewswire (Europe) | Daix (France), New York (United States), March 23, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 18.03. | Truist initiates Inventiva stock with buy on MASH therapy potential | 7 | Investing.com | ||
| 03.03. | Danaher, Moderna, Emyria: Drei Biotech-Aktien für die Beobachtungsliste im März 2026 | Small- & Micro Cap Investment | |||
| 26.02. | INVENTIVA: Inventiva to Participate in Four Upcoming March Investor Conferences | 471 | GlobeNewswire (Europe) | Daix (France), New York (United States), February 26, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 17.02. | Inventiva S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 17.02. | INVENTIVA: Inventiva reports preliminary 2025 fiscal year financial results | 620 | GlobeNewswire (Europe) | Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025Revenues of €4.5 million in 2025Completed a U.S. registered public offering for gross proceeds... ► Artikel lesen | |
| 04.02. | INVENTIVA: Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 | 378 | GlobeNewswire (Europe) | Daix (France), New York (United States), February 4, 2025 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen |
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 2,826 | -0,98 % | Aurora Cannabis Inc (3): Aurora granted Plant Breeders' Rights for two cultivars | ||
| VERTEX PHARMACEUTICALS | 382,05 | +1,62 % | VERTEX PHARMACEUTICALS INC / MA - S-8, Securities to be offered to employees in employee benefit plans | ||
| CRONOS GROUP | 2,252 | -0,27 % | Cronos Group Inc.: Cronos Group Reports 2026 First Quarter Results | Net revenue in Q1 2026 increased by 40% year-over-year to $45.2 million Achieved record net revenue and gross profit in Q1 2026 Reached #1 market share in vapes in Canada1 Ninth consecutive quarter... ► Artikel lesen | |
| VIATRIS | 14,090 | -0,61 % | Viatris übertrifft Gewinnprognose für Q1 2026 - Aktie legt deutlich zu | ||
| EYEPOINT | 10,900 | +1,87 % | EyePoint, Inc.: EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU, Building Confidence Ahead of Mid-2026 Topline Data | - LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after - - Continued favorable safety profile observed in masked Phase 3 DURAVYU data, consistent with four previously... ► Artikel lesen | |
| BAUSCH HEALTH | 4,654 | -0,30 % | Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference | ||
| EDWARDS LIFESCIENCES | 69,96 | -0,09 % | Edwards Lifesciences Appoints Theodora Mistras As Chief Financial Officer | WASHINGTON (dpa-AFX) - Edwards Lifesciences Corporation (EW) said that it has appointed Theodora Mistras as chief financial officer effective at the end of May.Mistras will join Edwards from... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 0,947 | +3,27 % | Transcript: OrganiGram Holdings Q2 2026 Earnings Conference Call | ||
| SNDL | 1,208 | -1,47 % | SNDL Inc.: SNDL Reports First Quarter 2026 Financial and Operational Results | EDMONTON, Alberta, April 29, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ: SNDL, CSE: SNDL) ("SNDL" or the "Company") reported its financial and operational results for the first quarter ended March... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 5,795 | -2,11 % | Quantum BioPharma Provides Corporate Update | THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, April 27, 2026... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 0,890 | 0,00 % | Happy Belly Food Group Inc.: Happy Belly Food Group Reports $19.3M in Q1 System Wide QSR Sales Up 80.4% Growth YOY | Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 13,565 | +0,22 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights | In the first full quarter since launch, 2,145 healthcare providers prescribed TONMYA, 3,588 patients initiated treatment, and ~5,400 prescriptions were filled Agreement signed in May with leading... ► Artikel lesen | |
| FILANA THERAPEUTICS | 1,020 | 0,00 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q1 2026 Financial Results and Business Update | AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| CANTOURAGE GROUP | 5,940 | -1,98 % | EQS-News: Cantourage Group SE: Cantourage steigert Profitabilität deutlich im ersten Quartal 2026 | EQS-News: Cantourage Group SE
/ Schlagwort(e): Quartals-/Zwischenmitteilung/Quartalsergebnis
Cantourage Group SE // Cantourage steigert Profitabilität deutlich... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 3,985 | -0,38 % | Lifeward Ltd.: Lifeward Successfully Closes on Strategic Partnership with Oramed | HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen |
Das Unternehmen INVENTIVA SA ADR kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,580 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INVENTIVA SA ADR finden Sie auf Wallstreet Online.